BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/0008-5472.can-22-2620
Abstract: PARP inhibition is a potential strategy for treating patients with gastric cancer with mutated BRCA2 or homologous repair deficiency, including patients with familial intestinal gastric cancer, for whom BRCA2 germline testing should be recommended. read more here.
Keywords: brca2 germline; mutations identify; germline mutations; gastric cancers ... See more keywords